 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH, Mereo or the Company, a clinical stage biopharmaceutical company focused on rare diseases, today announced the successful completion of a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration FDA to discuss the development of setrusumab, an anti-sclerostin antibody, for the treatment of children and adolescents with osteogenesis imperfecta OI. OI is a genetic rare disorder characterized by reduced bone mass and fragile bones that break easily. There are currently no approved treatments for OI. 